Chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA) is a class of engineered cellular immunotherapy in which a patient's own T cells are modified to recognize and eliminate malignant plasma cells, used as a treatment approach for relapsed/refractory multiple myeloma. Efficacy in this class is characterized by response-rate metrics (overall response rate, complete response rate) and depth-of-response measures such as minimal residual disease (MRD) negativity, assessed via sensitive tumor-cell detection methods, together with durability of response and a defined toxicity/safety profile as the framework for evaluating a therapy's clinical value. The domain sits within hematologic oncology and cellular immunotherapy, addressing the broader clinical goal of converting a historically fatal or chronic disease into one managed by long remission or potential cure.
Chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA) is a class of engineered cellular immunotherapy in which a patient's own T cells are modified to recog…